BioCardia (BCDA) News Today $1.92 +0.01 (+0.52%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.92 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period BioCardia, Inc.: BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical TrialApril 17 at 8:35 PM | finanznachrichten.deAlliance Global Partners Sticks to Its Buy Rating for BioCardia (BCDA)April 17 at 8:35 PM | markets.businessinsider.comBioCardia announces independent DSMB recommended CardiALLO-HF trial to continueApril 15, 2025 | markets.businessinsider.comBioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical TrialApril 15, 2025 | tmcnet.comBioCardia initiates enrollment at Emory University for CardiAMP HF II studyApril 11, 2025 | markets.businessinsider.comBioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal StudyApril 11, 2025 | globenewswire.comEarnings call transcript: BioCardia Q4 2024 sees reduced expenses, stock downApril 2, 2025 | uk.investing.comBioCardia’s CardiAMP-HF trial primary endpoint did not reach significanceApril 1, 2025 | markets.businessinsider.comBioCardia, Inc. (BCDA) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comBioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time TodayMarch 31, 2025 | globenewswire.comBioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 28, 2025 | uk.finance.yahoo.comBioCardia Reports 2024 Business Highlights and Financial ResultsMarch 26, 2025 | globenewswire.comBioCardia, Inc. to Report 2024 Financial Results and Host Conference Call Following CardiAMP-HF Trial PresentationMarch 23, 2025 | nasdaq.comBioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025March 21, 2025 | globenewswire.comBioCardia, Inc. Secures Japanese Patent for Innovative Catheter Delivery System in Cell TherapyMarch 12, 2025 | nasdaq.comBioCardia announces Japanese patent for Helix systemMarch 10, 2025 | markets.businessinsider.comBioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery SystemMarch 10, 2025 | globenewswire.comSimon H. Stertzer Acquires 22,753 Shares of BioCardia, Inc. (NASDAQ:BCDA) StockMarch 6, 2025 | insidertrades.comBioCardia Completes Source Data Verification for Phase 3 CardiAMP HF Study on Heart Failure TreatmentMarch 1, 2025 | nasdaq.comBioCardia finishes data freezing in heart failure therapy study for presentationFebruary 27, 2025 | markets.businessinsider.comBioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific SessionsFebruary 27, 2025 | globenewswire.comBioCardia completes enrollment for heart therapy trialFebruary 14, 2025 | msn.comBioCardia completes enrollment in low dose cohort in CardiALLO Phase I/II trialFebruary 13, 2025 | markets.businessinsider.comBioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)February 13, 2025 | globenewswire.comBiocardia CEO Peter Altman acquires $1,488 in common stockFebruary 11, 2025 | msn.comBiocardia CEO Peter Altman acquires $1,488 in stockFebruary 11, 2025 | msn.comBioCardia upgraded to Buy from Neutral at Alliance Global PartnersJanuary 31, 2025 | markets.businessinsider.comBioCardia, Inc. Announces Presentation of CardiAMP HF Phase 3 Study Results at ACC 2025 Scientific SessionsJanuary 29, 2025 | nasdaq.comBioCardia To Present Late-Breaking CardiAMP HF Trial Results At ACC 2025January 29, 2025 | nasdaq.comBioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific SessionsJanuary 27, 2025 | globenewswire.comPositive Outlook on BioCardia: Strategic Growth and Regulatory Advancements Drive Buy RatingDecember 18, 2024 | markets.businessinsider.comBioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product FamilyDecember 17, 2024 | markets.businessinsider.comBioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart FailureDecember 4, 2024 | globenewswire.comBioCardia Reports Q3 2024 Progress and FinancialsNovember 14, 2024 | markets.businessinsider.comBioCardia’s Strong Q3 Performance and Strategic Trials Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comBioCardia, Inc. (BCDA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comBioCardia Reports Third Quarter 2024 Business Highlights and Financial ResultsNovember 13, 2024 | markets.businessinsider.comPromising Outlook for BioCardia with Advancements in CardiAMP HF Program and Personalized Treatment ApproachOctober 29, 2024 | markets.businessinsider.comBioCardia completes last protocol specified follow-up visit in CardiAMP HFOctober 29, 2024 | markets.businessinsider.comBioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart FailureOctober 28, 2024 | markets.businessinsider.comBioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesOctober 9, 2024 | finance.yahoo.comBioCardia, Inc.: BioCardia Regains Full Compliance with Nasdaq Listing RequirementsSeptember 18, 2024 | finanznachrichten.deBioCardia Regains Full Compliance with Nasdaq Listing RequirementsSeptember 18, 2024 | globenewswire.comBioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesSeptember 9, 2024 | globenewswire.comBioCardia Announces FDA Market Clearance of Morph® DNA(TM) Steerable Introducer Product FamilyAugust 31, 2024 | stockhouse.comWhat In The World Is Going On With UTime (WTO) Stock Today?August 30, 2024 | benzinga.comEnsysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On?August 30, 2024 | msn.comWhy BioCardia (BCDA) Stock Is Falling TodayAugust 30, 2024 | msn.comBioCardia Shares Drop 10% After Public Offering PricesAugust 30, 2024 | marketwatch.comBioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesAugust 30, 2024 | tmcnet.com Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address BCDA Media Mentions By Week BCDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCDA News Sentiment▼0.240.58▲Average Medical News Sentiment BCDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCDA Articles This Week▼61▲BCDA Articles Average Week Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XLO News FBLG News FBRX News OKYO News ALVR News DYAI News CNTB News PEPG News XFOR News KPTI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCDA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCDA Stock Free BCDA Stock Alerts